Cytek Biosciences, Inc. (CTKB) Reports In-Line Q3 EPS ; Offers Guidance

Cytek Biosciences, Inc. (NASDAQ: CTKB) reported Q3 EPS of $0.01, in-line with the analyst estimate of $0.01. Revenue for the quarter came in at $51.5 million versus the consensus estimate of $50.7 million.

GUIDANCE:

Cytek Biosciences, Inc. sees FY2024 revenue of $203-210 million, versus the consensus of $203.9 million.

For earnings history and earnings-related data on Cytek Biosciences, Inc. (CTKB) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Venu Holding enters $250 million at-the-market stock offering agreement
• PreveCeutical closes second tranche of private placement for $245,000